There was no significant change over time observed for the PANSS positive symptoms or total score, or for the PANSS Hallucinatory Behavior item score. When assessing cognitive functioning, only Working Memory change was significant (p = 0.048) between the tDCS and the Control group with the tDCS group showing significant improvement in T-Score as compared to the Control group. Discussion: Subjects who received tDCS treatment showed a significant reduction in the frequency, number of voices, and total scores of their auditory hallucination. Additionally, subjects in the tDCS group showed significant improvement in the Working Memory. Our results indicate that patients who have been ultra-resistant to antipsychotic treatments and who received tDCS treatment presented with robust diminution of their auditory hallucinations. We conclude that tDCS seems to be effective not only for ambulatory, higher functioning patients, but also for much lower functioning patients with medication-refractory auditory verbal hallucinations. Methods: This was a randomised, double-blind, placebo-controlled trial conducted at the Early Psychosis Prevention and Intervention Centre (EPPIC) in Melbourne, Australia. One hundred and twenty patients aged 15-26 years with first-episode psychosis consented and were randomised to receive folic acid 5mg, vitamin B12 0.4mg, and vitamin B6 50mg or placebo, each taken once-daily for 12 weeks as an adjunct to antipsychotic medication. Co-primary measures were change in cognition as measured by a composite score from a battery of 11 tests and total symptomatology (PANSS) over 12 weeks. Secondary outcomes included additional cognitive, symptom, functioning, tolerability and safety measures. Results: Of the 120 participants randomised in the study, 20 dropped out with no follow-up assessments and were excluded from analysis. Of the remaining 100 participants, 52 were in the vitamins group and 48 the placebo group. At baseline, the two treatment groups had lower levels of folate and vitamin B12 intake than healthy controls, but did not differ from each other. Vitamin B12, B6 and folic acid reduced homocysteine levels in the vitamin group over 12 weeks. The homocysteine lowering effects of the vitamins did not confer a major advantage over placebo therapy in improving the co-primary PANSS (p=.75) or composite cognition (p=0.79) outcomes over 12 weeks. There was a significant difference between groups among females in the cognitive domain of speed of processing (p=.049) and attention/vigilance (p=0.002), in which the mean performance of the placebo group declined over 12 weeks, whereas performance in the vitamin group remained showed improvement. Discussion: Folic acid, B12 and B6 supplementation appears well tolerated and safe in first-episode psychosis and lowers homocysteine levels in this
Background: Vitamin B12, vitamin B6 and folic acid are homocysteinereducing agents. People with schizophrenia have been found to have increased homocysteine levels. Elevated homocysteine has been associated with impaired cognition. Previous research in chronic schizophrenia has shown that supplementation with folate plus vitamin B12 can improve cognition and clinical symptoms. Whether homocysteine lowering agents are effective in first-episode psychosis is unknown. The aim of this study was to investigate if adjunctive vitamin B12, B6 and folic acid can lower homocysteine and improve symptomatology and cognition in people with first-episode psychosis. Methods: This was a randomised, double-blind, placebo-controlled trial conducted at the Early Psychosis Prevention and Intervention Centre (EPPIC) in Melbourne, Australia. One hundred and twenty patients aged 15-26 years with first-episode psychosis consented and were randomised to receive folic acid 5mg, vitamin B12 0.4mg, and vitamin B6 50mg or placebo, each taken once-daily for 12 weeks as an adjunct to antipsychotic medication. Co-primary measures were change in cognition as measured by a composite score from a battery of 11 tests and total symptomatology (PANSS) over 12 weeks. Secondary outcomes included additional cognitive, symptom, functioning, tolerability and safety measures. Results: Of the 120 participants randomised in the study, 20 dropped out with no follow-up assessments and were excluded from analysis. Of the remaining 100 participants, 52 were in the vitamins group and 48 the placebo group. At baseline, the two treatment groups had lower levels of folate and vitamin B12 intake than healthy controls, but did not differ from each other. Vitamin B12, B6 and folic acid reduced homocysteine levels in the vitamin group over 12 weeks. The homocysteine lowering effects of the vitamins did not confer a major advantage over placebo therapy in improving the co-primary PANSS (p=.75) or composite cognition (p=0.79) outcomes over 12 weeks. There was a significant difference between groups among females in the cognitive domain of speed of processing (p=.049) and attention/vigilance (p=0.002), in which the mean performance of the placebo group declined over 12 weeks, whereas performance in the vitamin group remained showed improvement. Discussion: Folic acid, B12 and B6 supplementation appears well tolerated and safe in first-episode psychosis and lowers homocysteine levels in this population. However, supplementation may not offer extra benefits to all patients with first-episode psychosis, with the possible exception of speed of processing and attention/vigilance. Although previous research suggests that males preferentially benefit, our findings suggest that there may be a specific beneficial effect on cognition for females with first-episode psychosis. Methods: Data from three similarly designed, randomized, double-blind, placebo-controlled relapse prevention studies in adult patients with schizophrenia (DSM-IV-TR criteria) with similar inclusion/exclusion and relapse criteria were analyzed. Patients stabilized during an open-label stabilization phase with either paliperidone ER, PP1M or PP3M were then randomized to receive either placebo (analogous to non-adherent patients in the realworld) or the same active treatment used during stabilization phase (analogous to adherent patients). The primary outcome in each study was the time to relapse after entering the randomization phase, estimated using KaplanMeier method. In this report, the percentage of patients who relapsed as well as time to relapse in the three studies were indirectly compared. Results: In total 922 patients were included in this analysis, 473 continued to receive the same active treatment and 449 patients were randomized to receive placebo. The percentage of patients who relapsed was lowest with PP3M as compared with PP1M and paliperidone ER in both the active treatment group (PP3M, 9% < PP1M, 18% < paliperidone ER, 22%) and placebo group (PP3M, 29% < PP1M, 48% < paliperidone ER, 52%) patients. The post discontinuation median time to relapse (95% confidence interval) in placebo group was highest with PP3M, 395 days (274 days to not reached) > PP1M, 172 days (134 to 222 days) > paliperidone ER, 58 days (42 to 114 days) but was not estimable in the paliperidone group. Discussion: Treatment with longer acting formulations of paliperidone are associated with lower percentage of relapse and longer time to relapse in patients with schizophrenia. Lower percentage of patients with relapse observed with LAI therapy (PP1M and PP3M) could presumably be due to ensured therapeutic plasma levels. The lower percentage of relapse observed with PP3M treatment as compared with PP1M and oral paliperidone ER treatment in the placebo group could be advantageous to nonadherent patients, as this mimics the real-world scenario where patients discontinue their antipsychotics suddenly. These findings are of relevance in schizophrenia patients as fewer and delayed relapses over the course of a lifetime of schizophrenia may provide higher protection against grey matter damage and help preserve functioning. Background: Negative symptoms consist of impaired quality of life, social isolation, reduced emotional responsiveness, self-neglect and anhedonia, which have been categorised into avolition-apathy and expressive deficits sub-domains. The treatment of negative symptoms remains a challenge. Depression is commonly seen in schizophrenia and previous findings have suggested a relationship between depression and negative symptoms via the avolition-apathy sub-domain, (Barnes et al., 2016) . It is possible this is the result of a common aetiology, distinct from expressive deficit or other symptoms of schizophrenia. Immune dysfunction has been implicated in both psychotic and depressive illnesses; increased circulating pro-inflammatory markers (such as IL-6, TNF-α & CRP). This suggests a novel target for treatments. A putative neuroprotective role of minocycline has been suggested via reducing microglial activation, and decrease in the production of cytokines including IL-6. Minocycline has been shown to be effective in the treatment of negative symptoms (Xiang et al., 2017) and depression (Soczynska et al., 2012) . Within schizophrenia, we predict that that minocycline will lead to a longitudinal improvement in depression and the avolition-apathy sub-domain of negative symptoms Methods: Data from the BeneMin study will be presented. BeneMin recruited 207 patients with a current research diagnosis of schizophrenia within 5 years of onset and randomised to minocycline (300mg/day) or matching placebo for 12 months adjunctive to antipsychotic medication. For this analysis the primary outcome variable is the negative symptom subscale from the Positive and Negative Syndrome Scales (and broken down into avolition-apathy and expressive deficits sub-domains), Calgary Depression Scale in Schizophrenia (CDSS) and circulating IL-6, TNF-α and CRP over 4-time points 2, 6, 9, and 12 months. Results: At baseline, 40% were depressed (mean CDSS score = 5). The mean avolition-apathy PANSS score was 9.5 and expressive deficits was 9, and was comparable across placebo and minocycline arms. Preliminary results show that markers of inflammation were low in both treatment arms, compared with previous research (baseline CRP Md = 1.45, IL-6 Md = .57, TNF-α Md = 2.43) and this was comparable across depressed and nondepressed patients. TNF-α was significantly associated with expressivedeficits (B = .75, p = .005). Conversely, no marker of inflammation was associated with avolition-apathy or depression. However, in four linear mixed effect models across the 2, 6, 9 and 12-month follow-up assessments compared with placebo, minocycline had no effect on total negative symptoms, avolition-apathy, expressive deficits or depression. Further analysis stratifying patients by depression scores and markers of inflammation will be presented. Discussion: Preliminary results indicate that minocycline does not lead to a reduction in avolition-apathy or depression in early schizophrenia. This may be the result of a medicated, sample recruited within 5 years of illness onset, and low levels of depression. Future studies should target depression in psychosis as a primary aim with samples of individuals with increased inflammatory response to fully investigate minocycline's potential in targeted intervention. -16) contain numerous items that are rated based entirely or in part on observations of the subject during the interview. We hypothesized that inconsistency in the time of day of assessment in subjects whose symptoms were influenced by circadian rhythms could introduce an erratic "noise" element in the longitudinal measure of their symptoms.
T47. IS THERE
To investigate this hypothesis we compared the change in PANSS total score and individual PANSS items across consecutive visits by whether the assessments had been conducted at consistent vs. inconsistent times of day. Methods: 2109 individual subject visits from multiple schizophrenia clinical trials for which PANSS interview start time was available were included in the analysis. 1,764 pairs of consecutive PANSS interviews within individual subjects were identified and the time difference between the start times of the interviews were calculated. The absolute time difference was divided into quartiles and the first quartile (assessments least disparate in time) and the fourth quartile (assessments most disparate in time) were compared in the analyses. The mean absolute change in PANSS total and PANSS individual items between the consecutive visits was compared between the 2 groups using a t-test. Given the exploratory and hypothesis driven nature of the analysis we did not correct for multiple comparisons. Discussion: The results demonstrate a statistically significant effect of variation in time of day on symptom severity. These findings underscore the risk of potential noise (erratic changes) in longitudinal assessment of symptom severity when ratings are done at different times of day. Moreover, it suggests that symptom severity assessed in a standard PANSS interview may not generalize over the entire day, much less over the standard one week rating period. This is important because many PANSS items are rated partially or entirely on the interview which may not be a representative "biopsy" of the subject's mental state or behavior during the one week rating period. This highlights the potential remedies of more frequent or ecological measurements. Hufford et al (2014) demonstrated a statistically significant effect of variation in the time of day on signal from the MCCB cognitive battery. Our results confirm our anecdotal observations that severity of non-cognitive schizophrenic symptoms are impacted by circadian rhythms as well.
